Background It has been established that microRNA (miR)-449a is anti-tumorigenic in cancers, including lung cancer. Therefore, this study further explored miR-449a-mediated mechanism in lung cancer, mainly focusing on lysine demethylase 3A/hypoxia-induced factor-1 alpha (KDM3A/HIF-1 alpha) axis. Methods miR-449a, KDM3A and HIF-1 alpha levels in lung cancer tissues and cell lines (A549, H1299 and H460) were measured. Loss- and gain-of-function assays were performed and then cell proliferation, cell cycle, apoptosis, invasion and migration were traced. The relationship between KDM3A, miR-449a and HIF-1 alpha was verified. Tumor growth in vivo was also monitored. Results Both lung cancer tissues and cells exhibited reduced miR-449a and raised KDM3A and HIF-1 alpha levels. miR-449a interacted with KDM3A; HIF-1 alpha could bind with KDM3A. Up-regulating miR-449a hindered while suppressing miR-449a induced lung cancer development via mediating HIF-1 alpha. Elevating KDM3A promoted cellular aggression while down-regulating KDM3A had the opposite effects. Up-regulating KDM3A or HIF-1 alpha negated up-regulated miR-449a-induced effects on cellular growth in lung cancer. Restoring miR-449a impaired tumorigenesis in vivo in lung cancer. Conclusion It is eventually concluded that miR-449a delays lung cancer development through suppressing KDM3A/HIF-1 alpha axis.
第一作者单位:[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Thorac Surg, Tongji Hosp, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Hu Shan,Cao Peng,Kong Kangle,et al.MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1α axis[J].JOURNAL OF TRANSLATIONAL MEDICINE.2021,19(1):doi:10.1186/s12967-021-02881-8.
APA:
Hu, Shan,Cao, Peng,Kong, Kangle,Han, Peng,Deng, Yu...&Zhao, Bo.(2021).MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1α axis.JOURNAL OF TRANSLATIONAL MEDICINE,19,(1)
MLA:
Hu, Shan,et al."MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1α axis".JOURNAL OF TRANSLATIONAL MEDICINE 19..1(2021)